홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
COCP
#3816
Cocrystal Pharma, Inc. Common Stock
1.0
4
-2.80%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-2.80%
월간 변동
0.00%
6달 변화
-31.58%
년간 변동율
-40.23%
이전 종가
1.0
7
Open
1.0
2
Bid
Ask
Low
1.0
2
High
1.0
4
양
7
마켓
주식
헬스케어
COCP
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
5.96 M
8.12 M
8.14 M
10.17 M
10.17 M
—
Valuation ratios
Enterprise value
—
—
-20.2 M
-8.47 M
10.69 M
38.24 M
Price to earnings ratio
—
—
-0.44
-0.94
-1.17
-4.64
Price to sales ratio
—
—
945.49
-260.99
-126.08
-350.54
Price to cash flow ratio
—
—
-0.79
-1.16
-1.25
-4.68
Price to book ratio
—
—
0.43
0.64
2.16
3.33
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.18
-0.18
-0.95
-0.58
1.3
0.46
Return on equity %
0.18
-0.18
-0.98
-0.68
1.84
0.68
Return on invested capital %
186.85
—
1 324.77
2 801.62
2 921.49
—
Gross margin %
100
—
100
100
100
400
Operating margin %
475.97
—
215.72 K
-28.55 K
-10.97 K
96.7 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
479.05
—
-215.76 K
27.67 K
-10.74 K
-58.48 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
25.05
38.4
33.04
8.92
4.77
18.81
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.05
0
0
-0
-0.01
-0.01
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-2.63
-1.52
1.62
-0.31
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
4.57
2.73
0.97
2.82
Net current asset value per share
—
—
4.93
3.01
1.14
3.47
Tangible book value per share
—
—
4.86
2.73
0.94
2.88
Working capital per share
—
—
4.78
2.68
0.9
2.72
Book value per share
—
—
4.86
2.73
0.94
2.88
뉴스
Cocrystal Pharma advances norovirus drug candidate to Phase 1b trial
Tuesday’s Insider Activity: Major Buys at CBC, COCP; Sells at ARES, RKLB
필립 프로스트, 코크리스탈 파마(COCP) 주식 18,812달러 상당 매수
Phillip Frost buys Cocrystal Pharma (COCP) shares worth $18,812
Cocrystal Pharma raises $1.03 million in private placement from directors
Cocrystal Pharma receives $500,000 NIH grant for influenza drug
코크리스탈 파마, 470만 달러 규모의 등록된 직접 공모 마감
Cocrystal Pharma closes $4.7 million registered direct offering
코크리스탈 파마, 등록 직접 공모로 470만 달러 조달
Cocrystal Pharma raises $4.7 million in registered direct offering
코크리스탈, 노로바이러스 치료제 CDI-988 1b상 시험 진입
Cocrystal’s norovirus drug CDI-988 advances to phase 1b study